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Using small, flat aromatic rings as components of frag-
ments or molecules is a common practice in fragment-
based drug discovery and lead optimization. With an
increasing focus on the exploration of novel biological
and chemical space, and their improved synthetic
accessibility, 3D fragments are attracting increasing
interest. This study presents a detailed analysis of 3D
and 2D ring fragments in marketed drugs. Several
measures of properties were used, such as the type of
ring assemblies and molecular shapes. The study also
took into account the relationship between protein
classes targeted by each ring fragment, providing tar-
get-specific information. The analysis shows the high
structural and shape diversity of 3D ring systems and
their importance in bioactive compounds. Major differ-
ences in 2D and 3D fragments are apparent in ligands
that bind to the major drug targets such as GPCRs,
ion channels, and enzymes.
Key words: drug, fragment, lead optimization, ring
Received 31 May 2013, revised 24 September 2013 and
accepted for publication 4 November 2013
The success (1) in the last decade of fragment-based drug
discovery (FBDD) has led to the screening and design of
small fragments being common practice in many drug dis-
covery programs (2). The selection of fragment libraries is
usually done on the basis of molecular physical and chem-
ical properties, such as the rule of three (3,4). With the
increasing employment of diversity-oriented synthesis
(DOS), attention has focused on fragments’ skeletal diver-
sity and in particular on their degree of saturation and
structural, or shape, complexity (5,6). Saturation and com-
plexity are the two main properties that define the
so-called ‘3D fragments’ (7,8). Fragments comprising a
saturated core, with sp3 carbon atoms, are generally con-
sidered to have a three-dimensional character, as
opposed to planar or flat aromatic scaffolds. The saturated
core offers the possibility to access more globular shapes
and vectors for fragment expansion.
Aromatic ring scaffolds are often used in medicinal chem-
istry as they have more robust chemistry than 3D scaf-
folds. A variety of aromatic reagents are readily available
and they tend to be tractable substrates that can be sys-
tematically modified. Aromatic synthetic paths are well
characterized, with a number of metal-mediated couplings
in order to create aryl-aryl systems and C-C bond forming
reactions. For example, Suzuki and Sonogashira cou-
plings, Friedel-Crafts acylation and alkylation, are reactions
routinely used to selectively modify aromatic systems. Sat-
urated rings, however, are harder to substitute at the
desired positions and tend to rely on heteroatom alkylation
and arylation. C-C bond-forming reactions are less com-
mon and often generate stereocenters. Roughley and Jor-
dan have indeed noticed the presence of at least one
aromatic ring in 99% of the compounds present in their
dataset of medicinal chemistry reactions (9). Fragment-
based drug discovery (FBDD) has often focused on sp2-
rich aromatic compounds. However, molecules with
aromatic scaffolds can impair shape diversity, and possibly
limit the exploration of a subset of biological space. Sauer
et al. suggest that a screening library designed to contain
molecules with high molecular shape diversity would be
expected to show a broader range of biological activities
(10). Hung et al. proposed that DOS could be used to
generate fragments with enriched sp3 carbon content and
fragments with increased 3D character would give access
to a larger chemical space as compared to those libraries
currently in use, and would thus possibly allow addressing
‘difficult’ targets (5).
Lovering et al. (7) analyzed the effect of saturation and
complexity on molecule solubility and compound progres-
sion through the drug development stages. The research-
ers found that a higher proportion of sp3-hybridized
carbons was associated with increased solubility and with
compound success from discovery, through clinical test-
ing, to drugs. Similarly, researchers from GSK (11) sug-
gested that aromatic ring count negatively affects the
developability properties of lead compounds, being corre-
lated with lower solubility and higher lipophilicity, along
with other undesirable properties. Taken together, these
features can potentially lead to poorer efficacy and greater
toxicity. Conversely, hetero-aliphatic ring count correlated
with more desirable properties, such as increased solubil-
ity, decreased lipophilicity, and decreased albumin-binding
and cytochrome P450 inhibition (11,12). Clemons et al.
screened three sets of compounds, characterized by dif-
ferent degrees of saturation and structural complexity,
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against 100 sequence-unrelated proteins using small-mol-
ecule microarrays. They found that increasing the content
of sp3-hybridized atoms improved binding selectivity and
frequency, therefore resulting in improved performance of
screening collections (13). In a later follow-up analysis,
Clemons and colleagues, although clearly stating that a
causative relationship is not supported by their results,
suggested that specific binders tend in fact to have more
3D character than promiscuous compounds (14).
The success of FBDD is considerably dependent on the
quality of the fragment library used for screening; not only
the properties of the fragments but also what protein tar-
gets they are screened for. As suggested by the studies
mentioned above, employing more 3D fragments might
increase the diversity of fragment screening libraries,
improve their ADMET properties, and lead to better start-
ing points for lead generation and optimization. Rings and
ring systems play an essential role in drug scaffolds (15).
They represent systems of atoms where many degrees of
freedom are removed, give molecules their fundamental
shape, determine in large part the degree of flexibility of
the compound and the position of the side chains. A
detailed analysis of the 2D and 3D fragments found in
approved drugs, together with their intended protein tar-
gets can give further insights to the role of these fragments
in drug binding.
In this study, we define a fragment to be a contiguous sys-
tem of rings, i.e., all rings sharing at least one atom. In
addition, a 3D fragment must contain at least one sp3
hybridized carbon atom. Conversely, fragments with no
sp3 hybridized carbon atoms are defined as 2D. A simple
classification like this is easy to remember and would
enable scientists to use the information and put it into
practice. In addition, this system easily separates ring sys-
tems that are totally flat (2D). Figure 1 illustrates the defini-
tion of 2D and 3D fragments with the protease inhibitor
Indinavir. A further subset, 3D-h within 3D fragments is
defined as 3D hybrid/fused ring system containing both
pure 3D and aromatic rings. Comparison of 2D and 3D
rings was carried out with the use of shape and saturation
descriptors plus other property indices. The analysis also
takes into account the classes of their protein target, pro-
viding additional information and recording potential target-
dependent preferences toward flat or three-dimensional
rings. This data show the importance of 3D ring systems
in bioactive compounds, and indicates significant 2D/3D
ring preferences among different protein families.
Methods and Materials
Drug data set
The set of FDA approved drugs (version 19 March 2012)
was retrieved from DrugBank (16). The following structures
were filtered out using Pipeline Pilot 8.5:a drugs which are
nutraceuticals or contain elements other than carbon,
nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine,
bromine, or iodine. The usual chemical and physical prop-
erty filters, such as molecular weight or hydrogen bond
count, were not employed on this set of data. A final set
of 1297 drugs was obtained and they have the following
properties: molecular weight ranges 30.0–1736.2; AlogP
-18.7–14.2; hydrogen bond donors 0–37; hydrogen bond
acceptors 0–44; number of rotatable bonds 0–44.
Ring fragment definition
Pipeline Pilot 8.5 was used to generate ring fragments
from the molecules. The definition of ring assemblies,
including exocyclic double bonds, was used in the compo-
nent ‘Generate Fragments’. It generates contiguous ring
systems that share one or more atoms, including alpha
atoms only if they double bond with an atom that is part
of the ring (e.g., carbonyls in lactam compounds). Frag-
ments with no sp3 carbon atoms were defined as ‘2D
fragments’ while fragments with at least one sp3 carbon
atom were defined as ‘3D fragments’ as illustrated in Fig-
ure 1. Three dimensional-h (3D-h) is a subset of 3D frag-
ments denoting 3D hybrid/fused ring system containing
both pure 3D and aromatic rings. The number of sp3
hybridized carbons and total carbon count were calculated
using Pipeline Pilot 8.5.
Molecular similarity
An all-by-all Tanimoto matrix, built on Pipeline Pilot’s func-
tional-class fingerprints (FCFP_4), was generated for the
non-redundant set of fragments to assess their molecular
Figure 1: Definition of 2D and 3D ring fragments, using Indinavir
as an example. A ring fragment is defined as a ring assembly.
Fragments with no sp3 carbon are classed as 2D (green), the rest
as 3D (blue). 3D-h (light blue) is a subset of the 3D fragments,
denoting 3D hybrid/fused ring systems containing both pure 3D
and aromatic rings.
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similarity. Such a matrix is difficult to interpret and visual-
ize. Hence, a multidimensional scaling (MDS) technique
(17) was employed to extract the key information from this
matrix. MDS is a method whereby distance data can be
visualized in a small number of dimensions, e.g., a 2D or
3D map. The points representing molecular fingerprints are
arranged in the 2D plane in such a way that the root-
mean-square change in the distance when going from the
original matrix to the new representation is minimized. A
computer program employing this technique was written
in-house in the C programming language. To compare the
similarity of fragments within different protein targets, the
pairwise Tanimoto index between each fragment was sep-
arated for each target class, generating 15 matrices for
the 15 target classes studied here. A Kruskal–Wallis one-
way analysis of variance (K–W test) was performed using
these fifteen matrices, using the all-by-all matrix for all
non-redundant fragments as reference. This K–W test is a
non-parametric version of the one-way analysis of variance
and an extension of the Wilcoxon rank sum test for more
than two groups, and it compares the medians of the data
given as input in order to determine whether the samples
come from the same population. A significant result in the
K–W test means at least one sample comes from a differ-
ent population; however, it does not allow pair comparison
between samples. In order to estimate which groups (i.e.,
target classes) are significantly different from others, a mul-
tiple comparison test is needed. Therefore, Tukey’s hon-
estly significant difference method was used as post hoc
analysis in order to compare the samples. All statistics
were performed using Matlab R2012b.b
Molecular shape descriptor
Principal moments of inertia (PMI) ratios were used as
described by Sauer et al. as an indication of the molecular
shape of the fragments (10). The three PMIs (I1, I2, I3;
where I3 is the largest diagonal value) were calculated with
Pipeline Pilot 8.5, and a two-dimensional map was built
plotting the ratios I1/I3 versus I2/I3. A two-sample
Kolmogorov–Smirnov test (in Matlab) was also used in
order to compare the samples.
Target class assignment
Data on the biological targets of marketed drugs were
manually curated, starting from information retrieved from
DrugBank, EBI DrugPortc, and Overington et al. (18). Fif-
teen classes were defined. Six enzyme classes according
to the reaction they catalyze: oxidoreductases, transfer-
ases, hydrolases, lyases, isomerases, and ligases; and
three receptor classes: G-protein coupled receptors
(GPCR), nuclear receptors, and other receptors. The rest
were ion channels, penicillin-binding proteins, transporters,
cellular proteins, nucleic acids and ‘others’. Only the top
level of family classification was used in the study as the
statistics are only meaningful at the superfamily level. Each
of the 1191 drugs (of the 1232 drugs containing rings) has
one target class assignment. The 41 drugs remaining are
either chelating or contrast agents or simply did not report
any protein target in DrugBank.
Results and Discussion
Ring fragment profile
Only 65 of 1297 marketed drug molecules (about 5%)
have no ring structure, showing how important ring
assemblies are in drug skeletons. After ring fragmentation,
the remaining 1232 drug molecules have a total of 433
unique and non-redundant ring fragments, consisting of
101 2D and 332 3D fragments. Within the 3D fragments,
135 are 3D hybrid ring systems (3D-h). Figure 2 plots the
distribution of the number of ring fragments in drug mole-
cules. The majority of drugs (74%) contain one or two ring
assemblies. Fewer than 2% of the drug molecules have
five rings or more. This is not surprising as the molecular
weight (thus loosely related to number of ring fragments in
the drugs) of most drugs tend not to exceed 500 as
observed by Lipinski’s Ro5 (19).
The list of 2D and 3D ring fragments is provided in supple-
mentary Table S1. The ratio of 2D to 3D rings is about 1
to 3. There are in fact more unique 3D ring structures than
2D in this drug dataset. This could be because a saturated
ring can allow a larger variety of structures; e.g., in our
data set there are saturated 3-membered rings, such as
cyclopropane or oxirane, whereas unsaturated rings of this
size are usually poorly stable. Among all fragments, bicy-
clic and spiro-cyclic ring motifs are the most frequent (146
cases), followed by 113 cases of monocyclic ring systems
and 82 cases of tricyclic ring systems. Figure 3 plots the
distributions of the nature of the rings as well as ring size.
In 3D fragments mono-, bi-, and tri-cyclic rings represent
Figure 2: Ring fragment count distribution in our dataset of
marketed drugs.
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73% of fragments; there is in fact a higher presence of
more complex systems, made by four, five or more rings,
accounting for more than a quarter of all assemblies.
Three dimensional fragments provide more variety. Of the
332 three-dimensional assemblies, 197 (~60%) are pure
3D ring system, i.e., no fused aromatic ring at all. As
shown in Figure 3, systems containing only 3D single rings
and hybrid systems have relatively similar distributions of
number of rings within their assemblies and ring sizes.
Hybrid systems by definition cannot be monocycles and
tend to have slightly larger assemblies. 5- and 6-mem-
bered are the most frequently occurring rings for both
hybrid and 3D-only systems, both being found in more
than half of the assemblies, though 6-membered rings
absolutely dominate in hybrid systems, where, due to the
high frequency of the benzene motif, 131 of 135 3D-h
fragments contain at least one benzene motif. However,
3D-h systems do not contain 3- and 4-membered rings.
The absence of small rings is expected considering unsat-
urated cycles of this size are very unstable and, con-
versely, aliphatic 3- and 4-membered rings are already
strained systems that would be subjected to considerable
restraints if fused with an aromatic cycle. Thus, the pres-
ence of these small rings among 3D fragments is entirely
due to 3D-only systems.
The most popular 2D fragments are mono-, bi-, and tri-
cyclic rings covering 99% of all cases. In flat ring systems,
five- and six-membered rings are the most frequent,
occurring respectively in about 52% and 79% of all 2D
fragments. Also in three-dimensional fragments five and
six-membered rings are the most frequent (occurring
respectively in about 58% and 76% of fragments). How-
ever, there are also three-membered and four-membered
cycles. Seven-membered rings are represented in about
10% of 3D fragments with a similar proportion of more-
than-eight-membered rings. This incidence of large-sized
rings is due to the presence of natural compounds such
as cyclic peptides (e.g., Anidulafungin and Colistin). Con-
sidering aromaticity and sp2 hybridization impose consider-
able limitations on the number and arrangement of atoms
in a ring, it is noteworthy that 2D and 3D ring systems dif-
fer more in the number of rings present in the assembly,
which is not affected by the aromatic character, rather
than mere ring size. This might suggest that systems
made of four or five rings, where conjugation is broken by
the presence of tetrahedral carbons, may be better toler-
ated than similar systems where many unsaturated rings
are joined together.
To probe the 2D/3D combinations of the assemblies, Fig-
ure 4 displays the combinations of 2D and 3D ring sys-
tems found in marketed drugs. Four categories contribute
most frequently: drugs that have only one 3D ring frag-
ment (19.5%, e.g., Cevimeline); two ring fragments, one
2D and 3D ring fragment each (20.3%, e.g., Ramipril); one
2D ring fragment (15.7% e.g., Baclofen); and two 2D frag-
ments (12.3%, e.g., Omeprazole). These four cases cover
almost 70% of all the possible ring system combinations in
drugs. Overall, 32.9% of all drugs contain only 2D ring
assemblies, whereas 29.8% contain only 3D assemblies.
Taken together, these results suggest that in successful
bioactive compounds the proportion of flat ring systems to
three-dimensional, geometrically more complex, aliphatic
rings systems is in fact quite balanced, despite the general
notion that medicinal chemists tend to over employ aro-
matic rings with the intention of improving potency.
In order to qualitatively evaluate the shape diversity of the
2D and 3D fragments, we used PMI descriptors. In fact,
the sp3 carbon content does not directly describe the
actual shape of molecules and does not address the
A B
Figure 3: Ring type distributions among 2D and 3D ring fragments. (A) percentage of ring fragments containing at least one ring of the
specified size; e.g., 76.5% of 3D fragments and 79.2% of 2D fragments contain at least one 6-membered ring. (B) percentage of ring
fragments that are composed by one, two, three, four, five, or more rings.
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question of whether our 2D and 3D rings in fact show a
clear-cut difference in molecular shape. The result is a tri-
angular map (Figure 5) where the three corners represent
distinctive shapes, namely rod shapes (top-left corner) like
acetylene, disk shapes (lowest corner) like benzene, and
sphere shapes (top-right corner) like adamantane. Note
that the line between the corners that stand for the rod
and disk shapes represents flat compounds. The map only
describes molecular shapes, without considering any other
property; thus, benzene and pyridine essentially occupy
the same position on the plot due to their very similar
shape (an imperceptible difference in the position is due to
the different mass of the nitrogen and carbon atoms, influ-
encing their PMIs), albeit having different chemical proper-
ties. We assume that the further from the line a molecule
is, the less flat and more ‘three-dimensional’ it is. As
expected, 2D fragments are placed on the ‘flat line’, with
the exception of two outliers due to the presence of sulfo-
nyl groups. However, 3D fragments are scattered all over
the map, suggesting a much higher assorted distribution
of molecular shapes. In particular, the distribution of
3D-only assemblies seems to be more shifted toward a
globular shape as compared to the 3D-h system
(p = 7.2 9 1014 for a two-sample Kolmogorov–Smirnov
test between the two sets of geometric distances from the
top-right corner.) The small p-value from the Kolmogorov–
Smirnov test confirms that the presence of aromatic rings
will impact on the globular shapes of molecules. As sug-
gested by Sauer et al., although shape, together with size,
is probably one of the most basic and first levels in the
hierarchy of molecular descriptors, molecular shape diver-
sity is a prerequisite for broad bioactivity of screening
libraries (10). The map therefore suggests that 3D, ali-
phatic ring fragments have much to offer in terms of
molecular shape diversity; 2D aromatic systems tend to
offer less diversity, not only in terms of structure but also
in shape.
Fragments by target class
Target information was initially retrieved from the DrugBank
database and EBI DrugPort and then manually curated to a
final 15 target categories, with a single class assigned to
each drug as in Figure 6. The percentage distribution (the
values next to the target classes in Figure 6) of targets
among the marketed drugs set analyzed is similar to a previ-
ous study (18). Currently, the most common targets for small
molecule drugs are GPCRs (356 drugs), followed by ion
channels (138 drugs), and nuclear receptors (102 drugs).
With the above information, target classes were assigned
to fragments, based on the drugs containing them. Fig-
ure 6 plots the number of fragments as well as the per-
centage of 2D and 3D fragments against their protein
targets. Some target classes, such as GPCRs and ion
channels, have more fragments associated with them
compared to others (e.g., ligases and transporters). This is
because, as shown by Figure 6, currently there are more
A B
C
D
Figure 4: Combinations of 2D and
3D rings found in marketed drugs.
The graph shows the percentages
of the most common combinations
of 2D and 3D assemblies. These
associations represent 93.4% of
the whole data set. On the right,
A–D are examples of drug
molecules taken from the
respective 2D/3D fragment
combination groups; e.g. B,
Ramipril is a drug formed by one
2D and one 3D fragment.
Figure 5: Principal moments of
inertia (PMI) plot describing the
molecular shape for the rings
derived from marketed drugs. Two
dimensional rings on the left and
3D rings on the right. Notice the
more diverse distribution of shapes
for 3D rings as compared to 2D.
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GPCR or ion channels drugs than ligase or transporter
ones. In Figure 6, target classes are ordered in descend-
ing 3D fragment percentage content, so it is possible to
see the 3D fragment’s contribution. For instance, among
the fragment structures derived from nuclear receptors,
91.7% are 3D fragments, whereas among the structures
obtained from drugs targeting oxidoreductases only 50%
are 3D assemblies. In another example, if only the number
of 3D fragments are counted, the highest numbers are
103 in GPCRs, followed by 53 in ion channels, 48 in
hydrolases, and 44 in nuclear receptors. However, in
terms of percentages, strikingly, the highest percentages
of 3D fragments are found for 92% in nuclear receptors,
88% in transporters, and 86% in cellular proteins. Only
four target classes, all enzymes (ligases, lyases, oxidore-
ductases, and transferases), have an even distribution of
2D and 3D fragments in their drugs. Nevertheless, no tar-
get class has a higher 2D contribution than 3D.
Within the 3D sets in Figure 6, the 3D-only systems repre-
sent the vast majority within a target class. For example, in
nuclear receptors, penicillin-binding proteins, and nucleic
acids, 3D-only systems represent more than 80% of 3D
assemblies. The class of transporters shows instead a bal-
ance between the two 3D fragment subtypes, with exactly
50% of 3D-only and 50% of 3D-h. It seems that there is
no correlation between the percentage of 2D fragments
within a target class and the percentage of hybrid systems
within the 3D fragments of that class. This data give fur-
ther indication about what type of 3D ring systems might
be favored by a specific target class. However, care
should be taken as such target classes are very broad
and often contain a number of diverse protein families.
The implications of the size of the target classes will be
later discussed along with an analysis of fragment similarity
within each class, in order to highlight some possible
caveats of the study and be able to critically assess the
results. The ten most common fragments (i.e., the ten
most frequently occurring structures) shown in Table 1,
are associated with a high number of target classes. The
fragment phenyl, 1, exists in drugs that target all protein
classes; with the only exception being ligases, although in
our set of marketed drugs there are only 3 drugs targeting
ligases, none of them having phenyl. On the other hand,
fragment 10, a well-known motif of b-lactam antibiotics, is
associated with only one target class: penicillin-binding
proteins. Another example of a ring system targeting only
one class of protein, in spite of the fact it is found in many
different compounds, is fragment 25 (Table 2), the core of
benzodiazepines, which occurs in 14 different drug mole-
cules but targets specifically ligand-gated ion channels
(more precisely GABAA). Fragment 12 (a tricyclic), another
common and well-known 2D fragment, was found 25
times in 25 different drugs. For example, in antipsychotic
agents targeting dopamine receptors, such as Prochlor-
perazine and Propiomazine; antihistamine drugs, such as
Aceprometazine and Trimeprazine; and the drug Moricizine
targeting the sodium channel protein Nav1.5.
The results for the most frequent 3D fragments tell us that
hetero-aliphatic rings are more frequently employed than
the respective carbo-aliphatic rings with the same dimen-
sions. This observation is also in accordance with Ritchie
et al., who found higher hetero-aliphatic than carbo-
aliphatic ring counts in GSK medicinal chemistry com-
pounds (12). The factors contributing to such a discrepancy
can be different, from ease of synthesis to, more impor-
tantly, physicochemical properties. Aliphatic rings containing
heteroatoms might be favored due to the higher hydrophilic-
ity that typically leads to an increased compound solubility.
For instance, the aqueous solubility (logS) for cyclopentane,
tetrahydrofuran, and pyrrolidine is 2.64, 0.56, and 1.15,
respectively. A similar trend is observable with cyclohexane
(3.1), tetrahydropyran (0.03), and piperidine (1.07) (20).d
Moreover, the presence of a heteroatom can be functional
to the formation of interactions such as hydrogen bonds.
Figure 6: Number and percentage
of 2D and 3D rings per each target
class. Values in parentheses next to
the target categories are the
percentage distribution of targets
among the marketed drugs
analyzed. On the abscissa, the
number of rings (left) and their
percentage (right) in the target
class.
Chem Biol Drug Des 2014; 83: 450–461 455
Two and Three-dimensional Rings in Drugs
Carbo-aliphatic rings, on the other hand, generally do not
offer the opportunity of increased potency or improved
physicochemical properties. These reasons, in addition to
their lipophilic character, might be some of the causes of
their underrepresentation in drug molecules and medicinal
chemistry compounds. Among frequent 3D fragments, rings
coming from natural product structures are common,
e.g., b-lactams (16) and steroid scaffolds, targeting specifi-
cally penicillin-binding proteins and nuclear receptors,
respectively.
Next, we examined if any fragments are ‘privileged’ in terms
of target class. Table 2 lists the highest 16 fragments that
are present in at least five drugs and are only associated
with a single target class. 15 fragments are 3D ring assem-
blies, with only one 2D fragment (34). Fragment 34 is found
in nine drugs targeting bacterial topoisomerases. Note that
five fragments (27, 46, 47, 55, and 56) are steroid-type. A
few of these structures (e.g., 27 and 55) might appear to be
repeated, as they derive from different stereoisomers. Con-
trary to the most common 3D fragments listed in Table 1,
where 3D-only monocycles are by far the most commonly
employed systems, here most of the 3D systems are med-
ium size assemblies, comprising two, three or four rings,
and seven of fifteen 3D fragments are 3D hybrid systems.
Without careful experimental investigation, it is not possible
to determine whether the scaffolds/fragments present in
different drugs targeting the same protein not only contrib-
Table 1: The ten most frequent ring fragments found in marketed drugs
All rings 2D rings 3D rings
Noa Structure Frb FDrc Td No Structure Fr FDr T No Structure Fr FDr T
1 838 616 14 1 838 616 14 2 O 90 48 9
2 O 90 48 9 5 N 62 60 12 3 N 74 70 9
3 N 74 70 9 8
N
N 32 32 9 4
N
N 65 64 7
4
N
N 65 64 7 11
N
S 27 24 7 6 59 57 14
5 N 62 60 12 12
S
N 25 25 2 7 N 37 35 7
6 59 57 14 14
N
N
N
N
21 21 3 9 O 30 30 7
7 N 37 35 7 15
N
20 19 5 10
N
S
O
28 28 1
8
N
N 32 32 9 17 S 19 17 6 13 22 22 8
9 O 30 30 7 18
N
N 18 17 5 16
N
S
O
20 20 1
10
N
S
O
28 28 1 19 16 15 6 20
N N
O
O O
15 15 1
aNo is the fragment number (i.e., the numerical ID it was given).
bFr is the frequency (i.e., how many fragments with that structure were found in the set).
cFDr is the frequency (i.e., the number) of drugs containing the fragment (note how it does not correspond to Fr).
dT is the number of target classes (out of a total of 15) associated with the fragment. Explicit hydrogens are not drawn.
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ute to the binding affinity but also the specificity. However,
such ring systems have been successfully employed to tar-
get similar biomolecules, whereas other assemblies have
been exploited to target a multiplicity of protein classes,
suggesting they might unselectively contribute to binding.
Despite being aware of the hypothetical nature of this ratio-
nale, these results could corroborate the idea that 3D
assemblies may contribute to the specificity of a bioactive
compound more effectively than a two-dimensional ring
scaffold as suggested by Clemons et al. (14). In the context
of fragment-based drug design, 3D fragments might thus
constitute higher quality hits, offering also, as shown in the
previous section, a more diverse chemistry.
The differences recorded for the ring systems targeting dif-
ferent classes of biomolecules suggest that the fragments,
like the whole molecules, depend on the nature of the pro-
teins and their binding sites being targeted. When design-
ing fragments for screening, the protein target information
and the shape/saturation of the fragments are all quite
important to avoid the risk of underrepresenting 3D frag-
ments as compared to 2D aromatic assemblies.
Table 2: Ring fragments occurring in at least five drugs while being associated to a single target class
Noa Structure Frb FDrc Target Classd No Structure Fr FDr Target Class
10
N
S
O
28 28 PBP 46
O
6 6 NR
16
N
S
O
20 20 PBP 47 6 6 NR
20
HN NH
O
O O
15 15 IC 49 NH
HN
6 6 GPCR
25
N
H
N
O
14 14 IC 51 O
O
5 5 IS
27
O
12 12 NR 53
O
O 5 5 HS
28
N
H
N
12 12 GPCR 55
O
5 5 NR
34
N
H
O 9 9 IS 56
O
5 5 NR
41 O O 7 7 CP 34
S
5 5 GPCR
IC, Ion Channels; NR, Nuclear Receptors; CP, Cellular proteins, IS, Isomerases; HS, Hydrolases.
aNo is the fragment number.
bFr is the frequency (or count) in all drugs.
cFDr is the number of drugs containing the fragment (note that for this set of fragments it corresponds to the Frequency, which means
there is no drug holding one of these fragments twice).
dTarget Class is the single protein category with which the fragment is associated: PBP- Penicillin-binding proteins.
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Ring fragment similarity
To investigate the diversity among these rings, the non-
redundant fragment structures were compared by first cal-
culating an all-by-all similarity matrix using the Tanimoto
coefficient. The distribution of the Tanimoto values is plot-
ted in Figure 7A. The pairwise results showed the most
fragments are quite dissimilar (84.6% of fragment pairs
have Tanimoto less than 0.2); indicating that globally the
fragment set is very diverse.
The first 2 dimensions of the MDS of the set of fragments
is shown in Figure 7B, covering 33% of the original dis-
tance matrix. Aromatic rings such as benzene, naphtha-
lene, pyridine, pyrazine, imidazole, triazole, and indole are
clustered in the top-left corner of the plot. Some of these
fragments are among the most frequent ring assemblies
found in drug molecules. Below this cluster are 2D rings
characterized by the presence of carbonyl groups and het-
ero-aromatic tri-cyclic ring systems. These rings are found
in drugs such as the antipsychotic Enprofylline and the
antineoplastic Mitoxantron. The other 2D fragments on the
left-hand side of the map are mainly polycyclic. Three
dimensional fragments occupying the right-hand side of
the plot are highly saturated compounds, containing only
aliphatic rings, such as cyclohexane, piperazine, tetrahyd-
ropyran, some spiro compounds and the fused beta-lac-
tam structures that are the core of many antibiotics. 3D-h
fragments are positioned closer to 2D fragments on the
map as they share the same structure of some single
rings. The very top-right corner is populated by steroid-like
structures. Three dimensional fragments at the bottom-
right of the plot are monocycles characterized by the
presence of peptide bonds, such as b- and c-lactams and
cyclic peptides. In general, from this map is possible to
notice how 3D ring assemblies scatter more homoge-
neously on the plot, suggesting a slightly larger structural
diversity.
Next, the fragment similarity within each target class was
investigated. Since we defined broad target classes, each
class may consist of a number of protein sub-families rep-
resenting a different degree of biological diversity in terms
of proteins’ structures and functions. Although drugs tar-
geting the same protein may not necessarily bind to the
same site, fragments related to a small target class might
be more biased by the presence of compounds very simi-
lar to each other. Thus, in order to determine whether the
presence of particular compound classes would substan-
tially influence the outcome of the analysis, the pairwise
Tanimoto similarities for the fragments within each target
class were compared to those for all fragments. The
results (data not shown) showed that the fragments within
each target class have high diversity. As a general trend,
as seen in Figure 7A, more than 50% of Tanimoto scores
in all target classes are below 0.2. Eight classes out of fif-
teen have at least 90% of their Tanimoto scores below
0.3, including GPCRs, ion channels, oxidoreductases, and
transferases. Next, we applied the Kruskal–Wallis one-way
test for the Tanimoto scores for each target versus the
all-by-all fragments. The results in Figure 8 show that
seven target classes (in black) have comparable fragment
similarity to the group representing all non-redundant
fragments (Figure 7A). On the other hand, six classes
(hydrolases, ion channels, oxidoreductases, penicillin-bind-
A B
Figure 7: (A) Percentage distribution of Tanimoto scores for the whole set of non-redundant fragments. (B) The first 2 dimensions of the
multidimensional scaling (MDS) map of fragments. Three dimensional fragments are denoted by blue triangles and 2D fragments by green
diamonds. Some example molecules are shown, representing the structural characteristics of the fragments found in different clusters.
Notice the wider spread of 3D fragments on the map, suggesting a higher skeletal diversity.
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ing proteins, transferases and other receptors, in green)
have a similarity distribution shifted toward lower values,
indicating higher diversity as compared to the whole set
of fragments. The only two classes (in red) showing less
diversity than the reference are nuclear receptors and
transporters.
The high percentage of 3D fragments in nuclear receptors
is in fact influenced by the presence of many steroid-type
structures (e.g., 46, 47, 55, and 56 in Table 2). Their
fragment structures are unique to each other, although
very similar. On the other hand, 3D structures in trans-
porters seem not to be influenced by any particular type
of fragment and the class shows a very high degree of
fragment diversity with 89.3% of its Tanimoto scores
below 0.3. The set of ring systems within the cellular pro-
teins class shows low similarity. However, a closer
inspection of the structures reveals that the high propor-
tion of 3D fragments is largely due to the presence of
many natural macrocycles. In fact, 10 of the 28 fragments
in this category are rings composed of more than eight
atoms (e.g., 219, 244, 258, and 262 in Table S1) and are
mainly derived from macrolide antibiotics and anti-micro-
tubule agents. Even taking into account the similarity of
fragments within nuclear receptors and the presence of
many macrocycles within cellular proteins, it is hard to
deny the substantial contribution of three-dimensional
structures for these two target classes. Overall, for any
protein target in Figure 6, the presence of a 3D fragment
is quite important in the drug structure. When designing a
focused library, or selecting fragments for screening, it
may be useful to take into account the target class infor-
mation as well as structural information. From this analy-
sis, it seems that for some target classes, especially
receptors, such as nuclear receptors, transporters and
ion channels, 3D rings contribute positively toward good
lead compounds.
Conclusion
We carried out this study to analyze 2D and 3D fragments
in drugs as well as characterize their molecular profiles,
diversity, and target classes. Our data and analysis provide
useful information on the variety of fragments and their
properties, with the linking information on specific target
classes.
What first emerged from the study is that although flat aro-
matic scaffolds are widely employed, three-dimensional ali-
phatic ring fragments offer considerably greater structural
and shape diversity. The results support the hypothesis
that 3D fragments allow the sampling of a larger chemical
space. The presence of so many different 3D structures in
marketed drugs and their increased synthetic accessibility
is reassuring considering the suggested detrimental prop-
erties on drug candidates brought by a high aromatic ring
count.
Second, considerable differences in 3D ring presence
were recorded among different targets classes, such as
nuclear receptors, transporters, ion channels, and
GPCRs. It appears that the preference toward specific
scaffold shapes is likely to be highly target dependent.
This information can be taken into account in the context
of fragment library design in order to optimize 3D frag-
Figure 8: Fragment similarity comparison between different target classes. Each line represents the distribution of Tanimoto scores for
the fragments belonging to a specific target class. Shown are the location of the distribution and a 95% confidence interval (in blue dotted
box for the all-fragment sample). Two mean ranks are significantly different if their intervals do not overlap. Samples in red show a
significantly higher mean rank (lower diversity) from a chosen reference group, representing all the fragments (in blue). Samples in green
show a significantly lower mean rank (higher diversity) as compared to the reference.
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ment content, in particular when addressing drug targets
poorly amenable to flat compounds. Considering the
diverse characteristics of each protein class, the composi-
tion of a library should probably be a function of the bio-
logical target explored.
Finally, from the perspective of drug design, the appearance
of common ring fragments reflects the limited variability of
currently available chemical libraries from which drugs are
derived. Therefore, the results of this article will also be use-
ful in directing new synthetic chemical efforts toward poorly
explored areas of drug-like space.
Research on the effects of 3D rings on the frequency and
quality of fragment hits for different targets would contrib-
ute to knowledge in this area. Analysis into other data sets
(e.g., published medicinal compounds) might provide addi-
tional information on the contribution of 3D rings to bioac-
tive compounds and their protein targets.
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